Abstract This cross-sectional study compared the effects of treatment with atypical antipsychotic drugs on quality of life (QoL) and side effects in 218 patients with schizophrenia attending the ambulatory services of psychiatric in Rio Grande do Norte, Brazil. Socio-economic variables were compared. The five-dimension EuroQoL (EQ-5D) was used to evaluate QoL, and side effects were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale and the Simpson-Angus Scale. Data were analysed using the v 2 test and Student's t test, with a significance level of 5 %. Average monthly household incomes in the medication groups were 1.1-2.1 minimum wages ($339-$678). UKU Scale scores showed significant differences in side effects, mainly, clozapine, quetiapine and ziprasidone (p \ 0.05). EQ-5D scores showed that all drugs except olanzapine significantly impacted mobility (p \ 0.05), and proportions of individuals reporting problems in other dimensions were high: 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression. Psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent in users of atypical antipsychotic drugs, especially clozapine and ziprasidone. Olanzapine had the least side effects. QoL was impacted by side effects and economic conditions in all groups. Thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.
Introduction
Schizophrenia is a significantly disabling disease that affects all major areas of life [1] , it has been demonstrated consistently to have a major negative impact on quality of life, QoL [2] [3] [4] [5] . Numerous factors can affect QoL in patients with schizophrenia, including sociodemographic factors [6, 7] , symptomatological patterns of the disease [8] [9] [10] [11] , and side effects of antipsychotic medication [12, 13] .
Fujimaki et al. [14] found that chronic treatment with typical antipsychotic drugs had stronger negative effects on QoL than did treatment with atypical antipsychotic medications due to the greater incidence of side effects involving extrapyramidal symptoms. Similarly, Fang et al. [15] evaluated the effects of seven antipsychotic medications (chlorpromazine, sulpiride, clozapine, risperidone, olanzapine, quetiapine, and aripiprazole), and found that atypical antipsychotic drugs, especially olanzapine and quetiapine, were superior to typical antipsychotics in improving schizophrenic patients' QoL. In contrast, Chaves et al. [16] reported that patients taking risperidone and olanzapine had impaired or very impaired QoL, and that the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations.
Cascade et al. [17] showed that approximately 54 % of 353 respondents reported experiencing side effects of atypical antipsychotic medication. The most common side effects were weight gain, hunger, fatigue/lethargy, lack of coordination, and muscle problems (e.g. tenderness, twitches, and tremors) [17] .
In Brazil, although advances have been made in access to and choice of therapy for schizophrenia, few studies have examined the potential risks, side effects, and impact on QoL compared with second-generation antipsychotic drugs [16, [18] [19] [20] . The assessment of health-related QoL is essential because this parameter interferes with the choice of treatment; the results of such evaluation may provide a starting point for ambulatory services and rehabilitation. The five-dimension EuroQoL (EQ-5D) has been used to assess QoL in patients with chronic disease. This generic instrument evaluates all important healthrelated aspects and the impact of the disease on the individual. In this study, we used the EQ-5D to assess the impact of atypical antipsychotic use on QoL in patients with schizophrenia and evaluated the adverse effects of this treatment.
Materials and Methods
This cross-sectional study was conducted at the Dr. João Machado (Natal, RN, Brazil) and São Camilo (Mossoró, RN, Brazil) hospitals, and the Centre for Psychosocial Care Arte de Viver (Caicó, RN, Brazil). Adult patients (aged [18 years) diagnosed with schizophrenia according to the International Classification of Diseases 10 and Diagnostic and Statistical Manual of Mental Disorders IV criteria [21] who had received treatment with a secondgeneration atypical antipsychotic drug for C1 year were considered for inclusion in the study. Individuals \18 years old were excluded of the study. Participants and their family members provided written informed consent (protocol number 71235-CEP/UERN). The study was conducted in accord with the Declaration of Helsinki [22] .
Sample Size Calculation
In 2012, 5,000 patients of the ambulatory services of the participating institutions received atypical antipsychotic drugs (olanzapine, 34 %; risperidone, 33 %; ziprasidone, 13 %; clozapine, 10 %; quetiapine, 10 %). To calculate the appropriate sample size, we used a 95 % confidence interval and a 10 % tolerable sampling error. Considering the finite population and the prevalence of risperidone use (among antipsychotics atypical: lower cost), the following formula was used:
where n is the sample size, z a/2 is the confidence interval, P is the prevalence, N is the population, and e is the tolerable sampling error. The calculated sample size was 218 patients: 156 in Natal, 41 in Mossoró, and 21 in Caicó.
Data Collection
Economic and socio-demographic variables (age, sex, employment, household income, years of education, social security) were assessed using a structured questionnaire. Adverse events related to antipsychotic drug use were assessed using the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale [23] , which rates symptom severity and the perception or assessment that a symptom is a side effect. The UKU Scale is divided into four sections: psychiatric symptoms (10 items), neurological symptoms (8 items), autonomic symptoms (11 items), and other effects (19 items). The severity of each item is rated on a scale ranging from 0 to 3. The Simpson-Angus Scale, was developed in 1970 for the assessment of drug-induced parkinsonism and related extrapyramidal side effects [24] . This scale has demonstrated clinical validity and a high degree of inter-rater reliability. It comprises 10 items measuring rigidity (6 items), gait (hypokinesia), glabellar reflex, tremor, and salivation (1 item each). Each item is scored on a five-point scale ranging from 0 to 4. The total score is the sum of items divided by 10, with a total score [0.3 indicating the presence of extrapyramidal symptoms [25] .
QoL was assessed using the EQ-5D administered by interview, which evaluates 5Ds of health (mobility, self-help, habitual activities, pain, anxiety/depression) on a three-point scale ranging from 1 to 3. Item scores were dichotomised as 'no problem' (score = 1) or 'problems' (score = 2-3) to profile the frequencies of reported problems. The EQ-5D has been validated in Brazil [26] .
Data Analysis
Socio-economic, socio-demographic, and clinical variables were compared among atypical antipsychotic groups using the v 2 test and analysis of variance (ANOVA). EQ-5D, UKU Side Effect, and Simpson-Angus Scale scores were compared using ANOVA. A p value \0.05 was considered significant.
Results
The demographic characteristics of the study participants are shown in Table 1 . Significantly more men than women used antipsychotic drugs (p = 0.03). Average monthly household incomes in the medication groups were 1.1-2.1 minimum wages ($339-$678), and participants had low educational levels (B8 years in 80.8-100 % of individuals). The majority (69.2-90.3 %) of individuals were unemployed and 30.8-50 % received no social security. These characteristics did not differ significantly among groups.
Global score of Simpson-Angus Scale greater than 0.3 was observed for users of risperidone, quetiapine and clozapine (Table 2 ). Significant differences in UKU Side Effect Rating Scale scores were observed for the following items: memory difficulties (ziprasidone vs. quetiapine, p = 0.02), tension/restlessness (ziprasidone vs. quetiapine, p = 0.03), tremor (ziprasidone vs. risperidone, olanzapine, p = 0.01), epileptic seizures (clozapine/quetiapine vs. olanzapine/risperidone/ziprasidone, p \ 0.00), increased salivation (quetiapine vs. ziprasidone, p = 0.03), orthostatic dizziness (risperidone vs. olanzapine, p = 0.01), increased tendency to sweat (quetiapine vs. ziprasidone, p \ 0.00), rash (risperidone vs. olanzapine, p = 0.04), weight gain (quetiapine vs. ziprasidone, p = 0.05), galactorrhea (risperidone vs. olanzapine, ziprasidone, quetiapine, clozapine, p = 0.04), increased sexual desire (quetiapine vs. olanzapine, p = 0.031), decreased sexual desire (quetiapine vs. olanzapine, p \ 0.01), erectile dysfunction (quetiapine vs. olanzapine, p = 0.02; Table 3 ) and orgasmic dysfunction (quetiapine vs. olanzapine, p = 0.01).
High percentages of antipsychotic drug users reported difficulties in several EQ-5D dimensions that affected QoL (Fig. 1) . Mobility was significantly impaired by all medications except olanzapine (risperidone and clozapine, p \ 0.001; ziprasidone, p \ 0.01; quetiapine, p \ 0.05). No difference among medications was observed in the other dimensions, but many individuals reported problems. 63.6 % of clozapine users reported mobility problems, 63.7 and 56.3 % of clozapine and ziprasidone users, respectively, had difficulties with usual activities, 68.8 and 54.5 % of ziprasidone and clozapine users, respectively, experienced pain and/or discomfort, and 72.8 % of clozapine users reported anxiety and/or depression.
Discussion
The introduction of second-generation antipsychotic medications brought the promise of improved QoL for patients with schizophrenia, which has been confirmed in several studies [14, [27] [28] [29] . Conversely, high percentages of individuals in the present study reported difficulties in 5Ds of QoL associated with the compromised ability to perform daily activities. These findings are consistent with those of a previous study conducted in Brazil [16] , which showed significantly reduced QoL among patients with schizophrenia who used olanzapine and risperidone and no benefit associated with the use of second-generation antipsychotic drugs due to poor socio-economic conditions. This inconsistency in results may be related to socio-economic differences among patient groups that directly affect QoL. Users of atypical antipsychotic drugs in the present study lived in poor socioeconomic conditions, as reflected by low household incomes, low educational level, social security. In Brazil, improved access to care and therapeutic options have resulted in a shift from the treatment of schizophrenia and other mental illnesses. The Mental HealthCare Reform (2001) and Centres for Psychosocial Care reflect a policy of social inclusion for people with mental illnesses [30] . Other policies adopted by the Brazilian government have improved access to antipsychotic medication for the mentally ill; for example, the Specialised Programme for Pharmaceutical Assistance, part of the national health system, was created to ensure the completeness of drug treatment in outpatients whose care is defined in Therapeutic Guidelines and Clinical Protocols [31] . In addition, Ordinance 364 (clinical therapy guidelineschizophrenia) stipulates that all antipsychotic drugs except clozapine may be used in the treatment of schizophrenia, with no order of preference [32] . However, the results of this study suggest that the Brazilian governments' subsidy of second-generation antipsychotic drugs and related measures have not had the expected impact on users' QoL.
In addition to aggravating social conditions, the side effects of atypical antipsychotic medications impacted users' QoL in the present study. For example, the side effects of ziprasidone (memory difficulties and tension/restlessness) and clozapine (epileptic seizures) measured by the UKU Scale, as well as the total score of Simpson-Angus Scale for clozapine, may have impacted the dimension of anxiety/depression, pain/discomfort and usual activities. Only olanzapine did not affect mobility and resulted in no significant side effect. Corroborating this result, several authors have shown the superiority of olanzapine over other atypical antipsychotic drugs with respect to QoL [33, 34] . Thus, the use of second-generation antipsychotic drugs, particularly ziprasidone and clozapine, is associated with adverse effects, which in combination with poor living conditions may affect users' QoL. These findings suggest that anything impact a the introduction of next-generation drugs for patients living in poor socio-economic conditions.
Conclusion
We found that psychiatric, neurological, and autonomous adverse effects, as well as other side effects, were prevalent among users of second-generation antipsychotic drugs, especially ziprasidone and clozapine. Olanzapine was associated with few side effects, although all antipsychotic drugs were related to mobility problems. Many patients had low household incomes and were unemployed, thus, the effects of these antipsychotic agents appear to have been masked by aggravating social and economic situations. 
